HUTCHMED wins priority review in China for sovleplenib in wAIHA

HUTCHMED said on April 29, 2026, that China’s National Medical Products Administration has accepted its new drug application for sovleplenib in adults with warm antibody autoimmune hemolytic anemia, or wAIHA, and granted the filing priority review. The application covers patients who had an insufficient response to at least one prior glucocorticoid treatment. HUTCHMED said the filing is backed by data from the China Phase II/III ESLIM-02 study, including Phase III topline results announced in January 2026 showing the trial met its primary endpoint of durable hemoglobin response between weeks 5 and 24. The company also said the NMPA granted sovleplenib Breakthrough Therapy Designation for wAIHA in March 2026. (globenewswire.com)

Why it matters: While this is a human hematology story rather than a veterinary medicine development, it’s still relevant to animal health professionals tracking translational immunology and the regulatory momentum behind targeted therapies for immune-mediated blood disorders. Sovleplenib is an oral spleen tyrosine kinase, or Syk, inhibitor, aimed at interrupting Fc receptor and B-cell signaling involved in red blood cell destruction. In Phase II data published in The Lancet Haematology, HUTCHMED reported an overall response rate of 43.8% versus 0% for placebo in the first eight weeks, with a favorable safety profile, underscoring continued industry interest in more targeted alternatives to broad immunosuppression. (globenewswire.com)

What to watch: Next up will be full Phase III data disclosure, including the planned presentation at EHA 2026, and the NMPA’s review timeline under priority review. (globenewswire.com)